Quick Facts
FONT-SIZE Plus   Neg
Share SHARE
mail  E-MAIL

Teva Commences Launch Of Irbesartan And Irbesartan-hydrochlorothiazide Tablets

4/2/2012 1:13 AM ET

Generic drugmaker Teva Pharmaceutical Industries Ltd. (TEVA: Quote) Monday said it has commenced commercial launch of both irbesartan and irbesartan-hydrochlorothiazide tablets, the company's generic versions of Sanofi Aventis' high blood pressure treatments, Avapro and Avalide tablets.

The brand products had annual sales of around $464 million and $124 million, respectively, in the U.S., based on IMS sales data.

As the first company to file Abbreviated New Drug Applications containing paragraph IV certifications for both of these products, Teva has been awarded a 180-day period of marketing exclusivity.

Click here to receive FREE breaking news email alerts for Teva Pharmaceutical Industries Limited and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Chipmaker Advanced Micro Devices Inc. said Thursday after the markets closed that its first quarter loss narrowed from last year, helped by strong revenue growth in its graphics and visual solutions business. The company's quarterly earnings per share, excluding items, also came in above analysts' expectations as did its quarterly revenue. After trending higher over the past few sessions, stocks showed a lack of direction throughout the trading day on Thursday. The major averages spent the session bouncing back and forth across the unchanged line before ending the day mixed. While the major averages closed on opposite sides of the unchanged line, they all showed only modest moves. U.S. Secretary Of State John Kerry said Thursday that he and his counterparts from Russia, Ukraine and the European Union have reached an agreement on a preliminary plan for ending the ongoing crisis in Ukraine. Kerry was speaking at the end of the Ukraine contact group's first meeting, comprising the foreign ministers of Russia, Ukraine, the EU and the U.S., in the Swiss city of Geneva.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.